

Does CHA₂DS₂-VASc Score Predict MACE in Patients Undergoing Isolated Coronary Artery Bypass Grafting Surgery?

Muhsin Kalyoncuoglu¹, MD; Semi Ozturk¹, MD; Mazlum Sahin², MD



DOI: 10.21470/1678-9741-2018-0323

Abstract

Objective: To evaluate the prognostic value of CHA₂DS₂-VASc score in individuals undergoing isolated coronary artery bypass grafting (CABG) surgery.

Methods: Records of consecutive 464 patients who underwent elective isolated CABG, between January 2015 and August 2017, were retrospectively reviewed. A major adverse cardiac event (MACE) was the primary outcome of this study. MACE in patients with low (L) (<2, n: 238) and high (H) (≥2, n: 226) CHA₂DS₂-VASc scores were compared. Univariate logistic regression analysis identified predictors of MACE.

Results: Hypertension, diabetes mellitus, and peripheral vascular disease were more frequent in the H group than in the L group. European System for Cardiac Operative Risk Evaluation (EuroSCORE) I and SYNTAX I scores were similar in both groups while SYNTAX II-CABG score was significantly higher in the H group

than in the L group. Postoperative myocardial infarction, need for intra-aortic balloon pump, acute renal failure, and mediastinitis were more frequent in the H group than in the L group. The H group had significantly higher in-hospital mortality and MACE rates than the L group ($P < 0.01$). EuroSCORE I, SYNTAX II-CABG, and CHA₂DS₂-VASc scores were predictors for MACE. SYNTAX II-CABG > 25.1 had 68.4% sensitivity and 52.7% specificity (area under the curve [AUC]: 0.653, $P = 0.04$, 95% confidence interval [CI]: 0.607-0.696) and CHA₂DS₂-VASc > 2 had 52.6% sensitivity and 84.1% specificity (AUC: 0.752, $P < 0.01$, 95% CI: 0.710-0.790) to predict MACE. Pairwise comparison of receiver-operating characteristic curves revealed similar accuracy for both scoring systems.

Conclusion: CHA₂DS₂-VASc score may predict MACE in patients undergoing isolated CABG.

Keywords: Coronary Artery Disease. Coronary Artery Bypass – Adverse Effects. Length of Stay – Trends. Time Factors.

Abbreviations, acronyms & symbols

| | | | |
|-----------|---|-------|---|
| ACS | = Acute coronary syndrome | ICU | = Intensive care unit |
| AF | = Atrial fibrillation | IQR | = Interquartile range |
| AUC | = Area under the curve | L | = Low |
| BMI | = Body mass index | LDL-C | = Low-density lipoprotein cholesterol |
| CABG | = Coronary artery bypass grafting | LVEF | = Left ventricular ejection fraction |
| CAD | = Coronary artery disease | MACE | = Major adverse cardiac event |
| CI | = Confidence interval | MI | = Myocardial infarction |
| COPD | = Chronic obstructive pulmonary disease | OR | = Odds ratio |
| CPB | = Cardiopulmonary bypass | PAD | = Peripheral artery disease |
| CRP | = C-reactive protein | PCI | = Percutaneous coronary intervention |
| DM | = Diabetes mellitus | PVD | = Peripheral vascular disease |
| EuroSCORE | = European System for Cardiac Operative Risk Evaluation | ROC | = Receiver-operating characteristic |
| H | = High | SD | = Standard deviation |
| HDL-C | = High-density lipoprotein cholesterol | SE | = Standard error |
| Ht | = Hypertension | SPSS | = Statistical Package for the Social Sciences |
| HT | = Heart transplantation | STS | = Society of Thoracic Surgeons |
| IAB | = Intra-aortic balloon | TAVR | = Transcatheter aortic valve replacement |

¹Department of Cardiology, Haseki Training and Research Hospital, Istanbul, Turkey.

²Department of Cardiovascular Surgery, Haseki Training and Research Hospital, Istanbul, Turkey.

This study was carried out at the Haseki Training and Research Hospital, Department of Cardiology, Fatih, Istanbul, Turkey.

Correspondence Address:

Semi Ozturk

<https://orcid.org/0000-0001-5696-6849>

Haseki Training and Research Hospital, Department of Cardiology

Millet Caddesi No: 9, Aksaray, Fatih, Istanbul, Turkey

Zip Code: 34130

E-mail: semi_ozturk@yahoo.com

Article received on October 11th, 2018.

Article accepted on January 26th, 2019.

INTRODUCTION

Coronary artery bypass grafting (CABG) surgery and percutaneous coronary intervention (PCI) are widely used revascularization strategies for coronary artery disease (CAD) which reduce mortality and improve quality of life^[1]. Recent data suggested the superiority of CABG in preventing major cardiac events in patients with multivessel disease, particularly in patients with complex CAD and diabetes^[2].

The European System for Cardiac Operative Risk Evaluation (EuroSCORE) and the Society of Thoracic Surgeons (STS) 2008 Cardiac Surgery Risk Model are the most commonly used risk prediction models for cardiac surgery. These scoring systems are not only useful to assess the effect of specific clinical parameters on surgical outcomes, but also to aid in treatment selection, patient counseling, comparison of postoperative results, and quality improvement^[3]. Besides, current mortality risk prediction models for CABG do not have a standardized approach in terms of both defining predictor variables and outcome. In addition, some problematic topics such as inadequate sample size, inappropriate handling of missing data, as well as suboptimal statistical techniques make these risk models debatable^[4]. Need for calculator or computer make these models impractical for daily clinical use. Therefore, more practical risk modeling systems which predict morbidity and mortality are required.

CHADS₂ and CHA₂DS₂-VASC scores are well-validated and proposed scoring systems to establish the risk of stroke in patients with non-valvular atrial fibrillation (AF). Additionally, CHA₂DS₂-VASC score components, such as age, hypertension, diabetes mellitus (DM), and prior cardiovascular event, are also traditional risk factors for CAD. Previous studies demonstrated the association between the CHA₂DS₂-VASC score and the severity of CAD^[5]. Recent studies demonstrated the prognostic value of the CHA₂DS₂-VASC score in patients suffering from acute coronary syndrome (ACS)^[6].

Although CHA₂DS₂-VASC score is proposed as a predictor for immediate and late stroke after CABG, there is no data evaluating the prognostic value of CHA₂DS₂-VASC score in patients undergoing isolated CABG surgery^[7]. When compared with the aforementioned risk models, the CHA₂DS₂-VASC score is a fast and simple method for risk evaluation that requires no calculator or computers. We sought for the prognostic value of CHA₂DS₂-VASC score in individuals undergoing isolated CABG surgery.

METHODS

Study Population

This study included patients who underwent isolated CABG at the Haseki Training and Research Hospital between January 2015 and August 2017. The study excluded patients with concomitant other surgeries such as valve repair or replacement. Patients with preoperative AF were also excluded. Emergent procedures were excluded since preoperative assessments, such as carotid ultrasound, were insufficient. Records of 555 patients were retrospectively reviewed. Of these, 22 (3.9%) patients had an insufficient record, 14 (2.5%) underwent off-pump surgery, and 23 (4.1%) underwent concomitant other cardiac surgery (valvular, ventricular aneurysms, acquired ventricular septal defect). Additional 32 (5.8%) patients who underwent emergent surgery were excluded from the study.

All patients were operated by the same group of cardiovascular surgeons and anesthesiologists. Same techniques during CABG and myocardial protection were used.

The study population was retrospectively and consecutively analyzed by using our database, which was collected as a part of routine clinical practice. Data from each patient were obtained from a computerized system or a patient file. Demographic and laboratory variables including age, gender, body mass index (BMI), C-reactive protein, lipid panel, and clinical variables during hospitalization were recorded. Clinical variables included cardiopulmonary bypass (CPB) time, need for intra-aortic balloon (IAB), clamp time, total number of grafts, extubation time, bleeding revision, perioperative myocardial infarction (MI), sternal dehiscence, wound infection, cerebrovascular event (stroke or transient ischemic attack), mediastinitis, acute kidney injury, acute AF (lasting longer than one hour), intensive care unit (ICU) time, hospitalization time, and in-hospital mortality.

Risk Scores

SYNTAX I-II Score

The angiograms of the patients were evaluated by two experienced interventional cardiologists who were blind to the study. CAD was defined as a stenosis of more than 50% of the lumen diameter in any of the main coronary arteries. SYNTAX I-II scores were calculated by using the downloaded version (www.syntaxscore.com).

EuroSCORE I

Preoperative risk stratification was performed for all patients by using the downloaded version of the EuroSCORE system (euroscore.org).

CHA₂DS₂-VASC Score

CHA₂DS₂-VASC score was calculated for all patients by assigning one point for each of the following criteria: age 65-75 years, hypertension, DM, congestive heart failure or left ventricular ejection fraction (LVEF) < 40%, female sex, and vascular disease (defined as prior MI, complex aortic plaque, carotid disease, peripheral artery disease including intermittent claudication, and previous surgical or percutaneous intervention for abdominal aorta or vessels of upper or lower extremities). Two points were assigned for a history of stroke or transient ischemic attack or thromboembolism and age ≥ 75 years. Since all patients underwent coronary bypass surgery due to multiple CAD, CAD at index hospitalization was not taken into account. After the CHA₂DS₂-VASC score calculation, the study population was divided into two groups: low (L) (CHA₂DS₂-VASC < 2) and high (H) (CHA₂DS₂-VASC ≥ 2) score groups.

Study Endpoints

A major adverse cardiac event (MACE) was the primary endpoint of this study. MACE was defined as a composite of in-hospital mortality, postoperative non-fatal MI, cardiac arrest requiring cardiopulmonary resuscitation, need for new mechanical circulatory support, and cerebrovascular event during intraoperative/postoperative

hospitalization. In-hospital mortality was defined as death from all causes during intraoperative and postoperative hospitalization. The study was approved by the local ethics committee.

Statistical Analysis

Statistical analyses were performed with Statistical Package for the Social Sciences (SPSS) software version 22.0 (IBM Corp. Armonk, New York, United States of America) and MedCalc bvba version 16 (Seoul, Korea). Normality of the data was analyzed with the Kolmogorov-Smirnov test. Continuous data were expressed as mean \pm standard deviation (SD) and categorical data were expressed as percentages. Categorical variables between the groups were assessed with Chi-square test or Fisher's exact test, whichever was suitable. Logistic regression analysis was used to identify the independent predictors of MACE. Differences between patient subgroups were tested using Mann-Whitney U test or Student's t-test, where appropriate. A *P*-value < 0.05 was considered statistically significant. Receiver-operating characteristic (ROC) curve graphics were used to determine the cut-off values of predictors for MACE.

RESULTS

Four hundred sixty-four patients who underwent elective isolated CABG surgery were included in the study. Patients were dichotomized depending on their CHA₂DS₂-VASc score. L and

H score groups were compared as previously described. The L group included 238 patients (median age: 57 years [interquartile range {IQR}: 52-63]; 44 [18.5%] females) while the H group included 226 patients (median age: 64 years [IQR: 55-67]; 45 [19.9%] females). Hypertension, DM, and peripheral vascular disease (PVD) were more frequent in the H group (*P*<0.001, *P*<0.001, *P*=0.044, respectively) than in the L group. EuroSCORE I was similar in both groups (*P*=0.53). Anatomical based SYNTAX I score was similar in both groups, while clinical SYNTAX II-CABG score was significantly higher in the H group than in the L group (*P*=0.4, *P*=0.001, respectively). Postoperative MI was more frequent in the H group (*P*=0.006) than in the L group. Patients in the H group needed more IAB pump support (*P*=0.005) than those in the L group. Acute renal failure and mediastinitis in the postoperative period were more frequent in H group (*P*<0.001, *P*<0.001, respectively) than in the L group. Clinical, laboratory, and operative parameters were presented in Table 1 and Table 2. The H group had significantly higher in-hospital mortality and MACE rates than the L group (*P*<0.01).

When each component of CHA₂DS₂-VASc score was analyzed in univariate logistic regression analysis, congestive heart failure or ejection fraction < 40%, age, hypertension, PVD, and cerebrovascular event were independent predictors for MACE (Table 3).

We performed univariate analysis including EuroSCORE I, SYNTAX I and SYNTAX II, and CHA₂DS₂-VASc scores. EuroSCORE,

Table 1. Demographic, clinical, and laboratory characteristics of the groups.

| | CHA ₂ DS ₂ -VASc | | <i>P</i> |
|--|--|------------------|----------|
| | <2 n=238 | ≥2 n=226 | |
| Sex (female), n (%) | 44 (18.5) | 45 (19.9) | 0.32 |
| Age (years) | 57 (52-63) | 64 (55-67) | <0.001 |
| Body mass index (kg/m ²) | 27 (24.3-29.7) | 26.4 (24.2-29.5) | 0.19 |
| Smoking, n (%) | 99 (41.6) | 82 (36.3) | 0.24 |
| DM, n (%) | 19 (8) | 143 (63.3) | <0.001 |
| Ht, n (%) | 38 (16) | 147 (65) | <0.001 |
| COPD, n (%) | 34 (14.3) | 38 (16.8) | 0.45 |
| PAD, n (%) | 14 (5.9) | 43 (19) | 0.044 |
| CAD, n (%) | 36 (15.1) | 41 (18.1) | 0.38 |
| Stroke or transient ischemic attack, n (%) | 14 (5.9) | 9 (4) | 0.35 |
| Ejection fraction (%) | 55 (50-60) | 45 (40-60) | 0.03 |
| Total cholesterol | 240 (200-356) | 226 (208-310) | 0.47 |
| LDL-C | 116 (99.5-175) | 116 (100-175) | 0.94 |
| HDL-C | 45 (42-49) | 45 (42-51.8) | 0.48 |
| CRP | 5.5 (4-10) | 5 (4-9) | 0.70 |
| EuroSCORE I | 3 (2-4) | 3 (2-4) | 0.53 |
| SYNTAX I | 19 (14-25.5) | 19 (13-23.5) | 0.40 |
| SYNTAX II-CABG | 23.8 (21.3-28) | 25.7 (21.7-35) | 0.001 |

CABG=coronary artery bypass grafting; CAD=coronary artery disease; COPD=chronic obstructive pulmonary disease; CRP=C-reactive protein; DM=diabetes mellitus; EuroSCORE=European System for Cardiac Operative Risk Evaluation; HDL-C=high-density lipoprotein cholesterol; Ht=hypertension; LDL-C=low-density lipoprotein cholesterol; PAD=peripheral artery disease

Table 2. Operative and postoperative parameters of the groups.

| | CHA ₂ DS ₂ -VASc | | P |
|----------------------------------|--|---------------|--------|
| | <2 n=238 | ≤2 n=226 | |
| Bypass number | 3 (2-3) | 3 (2-3) | 0.36 |
| CPB time (min) | 92.5 (47-96) | 91 (47-96) | 0.16 |
| Clamp time (min) | 50 (26-55) | 48 (26-56) | 0.58 |
| Intra-aortic balloon pump, n (%) | 3 (1.3) | 14 (6.2) | 0.005 |
| Extubation time (hours) | 7 (5-9.5) | 7 (5-10) | 0.63 |
| Bleeding revision, n (%) | 9 (3.8) | 14 (6.2) | 0.23 |
| Hemorrhage (ml) | 500 (350-600) | 450 (350-600) | 0.73 |
| Sternal dehiscence, n (%) | 13 (5.5) | 10 (4.4) | 0.724 |
| Wound infection, n (%) | 12 (5) | 12 (5.3) | 0.89 |
| Mediastinitis, n (%) | 0 (0) | 12 (5.3) | <0.001 |
| Acute renal failure, n (%) | 1 (0.4) | 14 (6.2) | <0.001 |
| Acute atrial fibrillation, n (%) | 27 (11.3) | 25 (11.1) | 0.92 |
| Transient ischemic attack, n (%) | 0 (0) | 4 (1.9) | 0.056 |
| Stroke, n (%) | 1 (0.4) | 4 (1.8) | 0.34 |
| Post-operative MI, n (%) | 0 (0) | 7 (3.1) | 0.006 |
| In-hospital mortality, n (%) | 0 (0) | 14 (6.2) | <0.01 |
| MACE, n (%) | 1 (0.4) | 18 (8) | <0.01 |
| Intensive care unit time (day) | 2 (2-2) | 2 (2-3) | 0.91 |
| Hospitalization time (day) | 5 (5-6) | 5 (5-6) | 0.23 |

CPB=cardiopulmonary bypass; MACE=major adverse cardiac events; MI=myocardial infarction

Table 3. Logistic regression of each CHA₂DS₂-Vasc score component for MACE.

| Variables | P | OR (95% CI) |
|---|--------|--------------------|
| Congestive heart failure or ejection fraction < 40% | <0.001 | 12.3 (3.37- 44.87) |
| Sex | 0.87 | |
| Age | 0.01 | 1.13 (1.03-1.24) |
| Hypertension | 0.008 | 5.68 (1.56-20.61) |
| Diabetes mellitus | 0.08 | |
| Cerebrovascular event (stroke or transient ischemic attack) | <0.001 | 11.42 (3.5-37.28) |
| Peripheral vascular disease | 0.01 | 4.37 (1.4-1.52) |

CI=confidence interval; OR=odds ratio

SYNTAX II-CABG, and CHA₂DS₂-VASc scores were the predictors for MACE in logistic regression analysis (Hosmer-Lemeshow test, $P=0.414, 0.941, \text{ and } 0.693$, and Nagelkerke R Square, $P=0.359, 0.047, 0.105$; respectively) (Table 4). ROC curve analysis of SYNTAX II-CABG and CHA₂DS₂-VASc scores were performed to predict MACE (Figure 1). SYNTAX II-CABG > 25.1 had 68.4% sensitivity and 52.7% specificity to predict MACE (area under the curve [AUC]: 0.653,

$P=0.04$, 95% confidence interval [CI]: 0.607-0.696). CHA₂DS₂-VASc > 2 had 52.6% sensitivity and 84.1% specificity to predict MACE (AUC: 0.752, $P<0.01$, 95% CI: 0.710-0.790) (Table 5). We compared CHA₂DS₂-VASc with SYNTAX II-CABG, which is a relatively and comprehensive score. Pairwise comparison of ROC curves revealed the similar statistical accuracy of both scoring systems for prediction of MACE (Z statistic: 1.097, $P=0.27$) (Figure 2).

Table 4. Predictors of major adverse cardiac events; univariate logistic regression analysis of CHA₂DS₂-VASc, SYNTAX I, and SYNTAX II scores.

| Variables | Univariate analysis OR (95% CI) | P value |
|--|---------------------------------|---------|
| SYNTAX I | 1.00 (0.98-1.03) | 0.83 |
| SYNTAX II-PCI | 1.01 (0.99-1.02) | 0.30 |
| SYNTAX II-CABG | 1.07 (1.02-1.12) | 0.01 |
| EuroSCORE I | 2.71 (1.95-3.75) | <0.001 |
| CHA ₂ DS ₂ -VASc | 2.03 (1.41-2.92) | <0.001 |

CABG=coronary artery bypass grafting; CI=confidence interval; EuroSCORE=European System for Cardiac Operative Risk Evaluation; OR=odds ratio; PCI=percutaneous coronary intervention





Fig. 1 – Receiver-operating characteristic curve analysis of SYNTAX II-CABG and CHA₂DS₂-VASc for prediction of a major adverse cardiac event. AUC=area under the curve; CABG=coronary artery bypass grafting; CI=confidence interval

Table 5. Sensitivity and specificity of CHA₂DS₂-VASc to predict MACE.

| Criterion | Sensitivity | 95% CI | Specificity |
|-----------|-------------|-----------|-------------|
| ≥0 | 100 | 82.4-100 | 0.00 |
| >0 | 94.74 | 74.0-99.9 | 19.96 |
| >1 | 84.21 | 60.4-96.6 | 55.38 |
| >2 | 52.63 | 28.9-75.6 | 84.08 |
| >3 | 15.79 | 3.4-39.6 | 95.96 |
| >4 | 5.26 | 0.1-26.0 | 98.88 |
| >5 | 0.00 | 0.0-17.6 | 99.78 |
| >6 | 0.00 | 0.0-17.6 | 100 |

CI=confidence interval; MACE=major adverse cardiac event



| | Difference between areas | SE | 95% CI | Z statistic | P |
|--|--------------------------|--------|-------------------|-------------|--------|
| SYNTAX II-CABG CHA ₂ DS ₂ -VASc | 0.0990 | 0.0903 | (-0.0779)-(0.276) | 1.097 | 0.2727 |

Fig. 2 – Pairwise comparison of receiver-operating characteristic curves of SYNTAX II-CABG and CHA₂DS₂-VASc for prediction of a major adverse cardiac event. CABG=coronary artery bypass grafting; CI=confidence interval; SE=Standard error

DISCUSSION

We demonstrated, for the first time, that CHA₂DS₂-VASc score is an independent predictor for MACE in patients undergoing isolated CABG. Although CHA₂DS₂-VASc score includes only clinical parameters, it is as accurate as SYNTAX II-CABG, which includes a detailed angiographic evaluation.

CABG is a safe procedure with low rates of mortality and morbidity. However, the ability to accurately predict adverse outcomes and short- and long-term mortalities after CABG is an important issue that may allow planning preventive strategies and minimize complications^[8]. EuroSCORE, STS risk calculator, and Parsonnet score are the most commonly used risk stratification models which include multiple variables, requiring online calculators for estimation of risk-related mortality and morbidity with CABG^[9]. Nevertheless, these are complex and impractical tools to use at the bedside. Therefore, we still need models to quickly and easily predict risk at bedside, without the need for computational software. In practice, the bedside risk assessment not only provides the surgeon an objective, measurable risk profile to identify patients who require meticulous care, but it also provides the patients a more detailed knowledge of the risk related with the surgical procedure^[10].

CHA₂DS₂-VASc score is an easily applicable time-saving risk model which predicts the risk of thromboembolic events in patients with non-valvular AF in daily practice. CHA₂DS₂-VASc score components, such as older age, female gender, hypertension, DM, extracardiac arteriopathy, low LVEF, and preoperative stroke, and the presence of CAD were reported as predictors of early outcomes after CABG^[11].

The female sex has been reported as an independent predictor of short- and long-term mortalities and adverse events after CABG^[12]. Although the female sex is included in both STS and EuroSCORE, evidence is controversial. Several studies concluded that the female sex is not a risk factor for post procedural mortality after CABG^[13]. In our study, the female sex was not found to be associated with MACE, which is compatible with previous studies.

Increased age (> 60 years) has been reported as an independent predictor of mortality and adverse events after CABG^[14]. In the EuroSCORE model, 60 years of age was accepted as a cut-off value, thus one point was assigned per each five years above 60 years. In the CHA₂DS₂-VASc score, one point was assigned for 65-75 of age years and two points were assigned for age ≥ 75 years. Compatible with previous studies, our study demonstrated an association between age and MACE^[14].

Heart transplantation (HT) and DM are not included in the EuroSCORE risk model. On the other hand, HT, DM, and age were the predominant variables causing high scores in our study. Age and HT were independent predictors for MACE in the present study. Although several studies revealed that patients with DM are at high risk for MACE and death after CABG, univariate analysis revealed that DM was not an independent predictor for MACE in the present study, like studies by Rajakaruna et al.^[15]. These conflicting data may be related to defining the criteria of DM. DM was defined as the need for insulin or oral medication in the present study, while another study defined DM as the need for diet, oral medication, or insulin therapy^[16]. Patients with insulin-dependent DM have a significantly higher rate of mortality and MACE than those with non-insulin-dependent DM^[17]. We also did not classify DM as insulin-dependent or non-dependent. These might explain the different outcome associated with diabetes on early mortality in the present study.

Although there is conflicting data in the literature, we showed that preexisting HT is a poor predictor for patients undergoing isolated CABG^[18]. CABG has been shown to be superior to medical therapy alone in patients with preoperative low LVEF^[19]. Besides, Dalen et al. showed that the reduced ejection fraction doubled the risk of early postoperative death^[20]. Compatible with the previous studies, patients with left ventricular systolic dysfunction and symptoms of heart failure had significantly high in-hospital mortality and morbidity in our study^[9].

Similar to our study, numerous studies have demonstrated that the PVD was an independent predictor of early mortality and poor short-term outcome after CABG^[21]. On the other hand, the association between PVD and early mortality was not confirmed in some studies^[22].

History of stroke has been found to be associated with mortality and increased early and late postoperative stroke^[23]. In line with the literature, the present study demonstrated that a history of preoperative stroke was associated with poor outcome.

Consequently, when we performed univariate analysis of each CHA₂DS₂-VASC score component, congestive heart failure or ejection fraction < 40%, age, hypertension, cerebrovascular accident, and PVD were significantly associated with MACE in patients undergoing after isolated CABG, whereas DM and sex were not.

Several studies have demonstrated an association between the CHA₂DS₂-VASC score and increased mortality and non-fatal adverse cardiovascular outcomes in different clinical conditions, regardless of the presence of AF^[24]. Recently, Hamid et al. observed high mortality in the patients undergoing transcatheter aortic valve replacement who had CHA₂DS₂-VASC score > 6. Therefore CHA₂DS₂-VASC score was proposed as a simple tool for the identification of high-risk patients for short-term and mid-term mortalities in patients undergoing transcatheter aortic valve replacement (TAVR)^[25].

This the first study which aimed to investigate the value of CHA₂DS₂-VASC score to estimate MACE in patients undergoing isolated CABG surgery. Biancari et al. demonstrated predictive accuracy of CHA₂DS₂-VASC score for immediate and late stroke in patients after CABG without pre- and postoperative AF. They also demonstrated that CHA₂DS₂-VASC score is a predictor for late all-cause mortality and cardiovascular mortality^[8]. But there is no data specifically evaluating the value of CHA₂DS₂-VASC score for prediction of in-hospital mortality and MACE in patients undergoing isolated CABG.

Limitation

The major limitation of our study is that we focused on the CHA₂DS₂-VASC score, which only includes the preoperative variables, and we did not take operative and postoperative variables into account. In the recent years, more complex preoperative patient profile was being referred for CABG due to improved medical treatment options and achievements of interventional cardiology. As preoperative variables may have limited predictor role without combination with operative and postoperative variables, larger studies including preoperative, operative, and postoperative variables are required. The second limitation was that the surgery was performed by a particular surgeon group. And another limitation is the retrospective nature of the study. So this study is single-centered and may not be generalized to all patient groups.

CONCLUSION

We showed that CHA₂DS₂-VASC score may predict in-hospital mortality and MACE in patients undergoing isolated CABG in our study population. CHA₂DS₂-VASC score is a handy risk stratification score and easily applicable at bedside without any computational software. Further studies are required to assess the validity of our findings in larger populations.

No financial support.

No conflict of interest.

Authors' roles & responsibilities

| | |
|-----------|--|
| MK | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published. |
| SO | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published. |
| MZ | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published. |

REFERENCES

1. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al; BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med.* 2009;360(24):2503-15. doi:10.1056/NEJMoa0805796.
2. Mohr FW, Morice MC, Kappetein, Feldman TE, Ståhle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. *Lancet.* 2013;381(9867):629-38. doi:10.1016/S0140-6736(13)60141-5.
3. Shahian DM, O'Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB, et al; Society of Thoracic Surgeons Quality Measurement Task Force. The society of thoracic surgeons 2008 cardiac surgery risk models: part 1 – coronary artery bypass grafting surgery. *Ann Thorac Surg.* 2009;88(1 Suppl):S2-22. doi:10.1016/j.athoracsur.2009.05.053.
4. Karim MN, Reid CM, Cochrane A, Tran L, Alramadan M, Hossain MN, et al. Mortality risk prediction models for coronary artery bypass graft surgery: current scenario and future direction. *J Cardiovasc Surg.* 2017;58(6):931-42. doi:10.23736/S0021-9509.17.09965-7.
5. Cetin M, Cakici M, Zencir C, Tasolar H, Baysal E, Balli M, et al. Prediction of coronary artery disease severity using CHADS2 and CHA2DS2-VASC scores and a newly defined CHA2DS2-VASC-HS score. *Am J Cardiol.* 2014;113(6):950-6. doi:10.1016/j.amjcard.2013.11.056.
6. Chua SK, Lo HM, Chiu CZ, Shyu KG. CHA2DS2-VASC score predicts intracoronary thrombus burden in patients with ST-elevation myocardial infarction. *Biomed Res.* 2017;28(18):8050-4.
7. Biancari F, Asim Mahar MA, Kangasniemi OP. CHADS2 and CHA2DS2-VASC scores for prediction of immediate and late stroke after coronary artery bypass graft surgery. *J Stroke Cerebrovasc Dis.* 2013;22(8):1304-11. doi:10.1016/j.jstrokecerebrovasdis.2012.11.004.
8. Antunes PE, de Oliveira JF, Antunes MJ. Risk-prediction for postoperative major morbidity in coronary surgery. *Eur J Cardiothorac Surg.* 2009;35(5):760-6; discussion 766-7. doi:10.1016/j.ejcts.2008.10.046.
9. Kamal YA, Al-Elwany S, Ghoneim A, El-Minshawy A. Traditional predictors of in-hospital mortality after coronary artery bypass grafting: Current status. *Cardiothorac Vasc Sci.* 2017;1(2):1-5. doi:10.15761/CVS.1000107.
10. Ad N, Barnett SD, Speir AM. The performance of the EuroSCORE and the society of thoracic surgeons mortality risk score: the gender factor. *Interact Cardiovasc Thorac Surg.* 2007;6(2):192-5. doi:10.1510/icvts.2006.138313.
11. Kamal YA, Al-Elwany SE, Ghoneim A, El-Minshawy AK. Predictors of early adverse events after isolated coronary artery bypass grafting: Current status. *Austin J Clin Cardiol [Internet].* 2017 [cited 2019

- Apr 27];4(2):1059. Available from: <http://austinpublishinggroup.com/clinical-cardiology/fulltext/ajcc-v4-id1059.pdf>.
12. Alam M, Bandedali SJ, Kayani WT, Ahmad W, Shahzad SA, Jneid H, et al. Comparison by meta-analysis of mortality after isolated coronary artery bypass grafting in women versus men. *Am J Cardiol*. 2013;112(3):309-17. doi:10.1016/j.amjcard.2013.03.034.
 13. Faerber G, Zacher M, Reents W, Boergermann J, Kappert U, Boening A, et al. Female sex is not a risk factor for post procedural mortality in coronary bypass surgery in the elderly: A secondary analysis of the GOPCABE trial. *PLoS One*. 2017;12(8):e0184038. doi:10.1371/journal.pone.0184038.
 14. Safaie N, Montazerghaem H, Jodati A, Maghamipour N. In-hospital complications of coronary artery bypass graft surgery in patients older than 70 years. *J Cardiovasc Thorac Res*. 2015;7(2):60-2. doi:10.15171/jcvtr.2015.13.
 15. Rajakaruna C, Rogers CA, Suranimala C, Angelini GD, Ascione R. The effect of diabetes mellitus on patients undergoing coronary surgery: a risk-adjusted analysis. *J Thorac Cardiovasc Surg*. 2006;132(4):802-10. doi:10.1016/j.jtcvs.2006.05.056.
 16. Szabó Z, Håkanson E, Svedjeholm R. Early postoperative outcome and medium-term survival in 540 diabetic and 2239 nondiabetic patients undergoing coronary artery bypass grafting. *Ann Thorac Surg*. 2002;74(3):712-9. doi:10.1016/S0003-4975(02)03778-5.
 17. Raza S, Sabik JF, Ainkaran P, Blackstone EH. Coronary artery bypass grafting in diabetics: a growing health care cost crisis. *J Thorac Cardiovasc Surg*. 2015;150(2):304-12.e2. doi:10.1016/j.jtcvs.2015.03.041.
 18. Vavlukis M, Borozanov V, Georgievska-Ismail LJ, Bosevski M, Taneva B, Kostova N, et al. Arterial hypertension in patients with coronary artery disease treated with surgical myocardial revascularization. *Bratisl Lek Listy [Internet]*. 2007 [cited 2019 Apr 27];108(7):301-6. Available from: <https://core.ac.uk/download/pdf/35341402.pdf>.
 19. Wrobel K, Stevens SR, Jones RH, Selzman CH, Lamy A, et al. Influence of baseline characteristics, operative conduct and postoperative course on 30-day outcomes of coronary artery bypass grafting among patients with left ventricular dysfunction: results from the surgical treatment for ischemic heart failure (STICH) trial. *Circulation* 2015;25;132(8):720-30. doi:10.1161/CIRCULATIONAHA.114.014932.
 20. Dalen M, Lund LH, Ivert T, Holzmann MJ, Sartipy U. Survival after coronary artery bypass grafting in patients with preoperative heart failure and preserved vs reduced ejection fraction. *JAMA Cardiol*. 2016;1(5):530-8. doi:10.1001/jamacardio.2016.1465.
 21. Birkmeyer JD, O'Connor GT, Quinton HB, Ricci MA, Morton JR, Leavitt BJ, et al. The effect of peripheral vascular disease on in-hospital mortality rates with coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. *J Vasc Surg [Internet]*. 1995 [cited 2019 Apr 27];21(3):445-52. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/7877226>.
 22. van Straten AH, Firanesco C, Soliman Hamad MA, Tan ME, Woort JF, Martens EJ, et al. Peripheral vascular disease as a predictor of survival after coronary artery bypass grafting: comparison with a matched general population. *Ann Thorac Surg*. 2010;89(2):414-20. doi:10.1016/j.athoracsur.2009.11.036.
 23. Anyanwu AC, Filsoufi F, Salzberg SP, Bronster DJ, Adams DH. Epidemiology of stroke after cardiac surgery in the current era. *J Thorac Cardiovasc Surg*. 2007;134(5):1121-7. doi:10.1016/j.jtcvs.2007.06.031
 24. Puurunen MK, Kiviniemi T, Schlitt A, Rubboli A, Dietrich B, Karjalainen P, et al. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. *Thromb Res*. 2014;133(4):560-6. doi:10.1016/j.thromres.2014.01.007.
 25. Hamid T, Choudhury TR, Anderson SG, et al. Does the CHA2DS2-VASc score predict procedural and short-term outcomes in patients undergoing transcatheter aortic valve implantation? *Openheart*. 2015;2(1):e000170. doi:10.1136/openhrt-2014-000170.

